Lixisenatide molecular structure
Lixisenatide molecular structure
Approved
🏋️Weight Loss

Lixisenatide

Also known as: Adlyxin, Lyxumia, AVE0010, ZP10

MW

4858.50 Da

Formula

C215H347N61O65S

CAS

320367-13-3

Routes

1 route

Lixisenatide is a once-daily GLP-1 receptor agonist derived from exendin-4 with modifications including a C-terminal hexa-lysine extension. Developed by Sanofi, it is approved as Adlyxin (US) and Lyxumia (EU) for type 2 diabetes. Lixisenatide has a shorter half-life (~3 hours) compared to long-acting GLP-1RAs, producing a pronounced postprandial glucose-lowering effect through robust gastric emptying delay. Its unique pharmacokinetic profile makes it particularly effective for postprandial glucose control and it is available in a fixed-ratio combination with insulin glargine (Soliqua/iGlarLixi), combining basal insulin with prandial GLP-1RA coverage.

Research Use Only— For educational and research purposes only

Research Applications

Type 2 Diabetes (Approved)

Postprandial glucose specialist. HbA1c reduction 0.7-0.9%. ELIXA trial confirmed cardiovascular safety (neutral on MACE).

Combination with Basal Insulin

Fixed-ratio combination with insulin glargine (Soliqua) provides complementary fasting + postprandial coverage.

Mechanism of Action

Lixisenatide activates GLP-1R with effects biased toward gastric emptying delay and postprandial glucose control. Its shorter duration of action produces more pronounced gastric slowing than long-acting agents, significantly blunting postprandial glucose excursions. Standard GLP-1R signaling drives insulin secretion and glucagon suppression.

Biological Pathways

GLP-1R/cAMP/PKA beta cell signaling. Vagal afferent and central pathways for pronounced gastric emptying delay. Modest central appetite effects compared to longer-acting GLP-1RAs.

Dosage Information

Typical dosage ranges for research applications. Always verify with current literature.
Typical Dose
20 mcg
Dose Range
10 - 20 mcg
Frequency
Once daily within 1 hour before first meal; start at 10 mcg for 14 days
Dosage Calculator
Calculate precise peptide dosages based on your reconstitution parameters
Dosage calculation parameters
Vial size in milligrams
Reconstitution volume in milliliters
Body weight input
Recommended dose per kg
mcg/kg
Desired dose input
mcg

Calculation Results

Concentration
2.5 mg/ml
Dose Volume
0.1 ml0.100 ml
Insulin Syringe
10 units
Doses per Vial
2020 doses @ 250 mcg

Syringe Fill Level (100u syringe)

05010010.0uunits
0u10.0 / 100 units (10%)100u

Protocols

No protocols featuring this peptide yet.

Browse All Protocols

Stability & Storage

Store at 2-8°C before first use. After first use, store below 30°C for up to 14 days. Protect from light.

Side Effects & Precautions

Nausea (25%), vomiting (10%), diarrhea (8%). GI effects more pronounced initially but resolve over weeks. Lower systemic GI effects compared to long-acting agents. Injection site reactions. Hypoglycemia risk when combined with sulfonylureas or insulin.

Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.

Regulatory Status

Approved

FDA-approved (2016) as Adlyxin. EMA-approved as Lyxumia. Also approved in fixed combination as Soliqua (with insulin glargine). WADA-prohibited under S2.

Research Studies

Lixisenatide Cardiovascular Safety (ELIXA)

Pfeffer MA, Claggett B, Diaz R, et al.

New England Journal of Medicine
2015
View Source

iGlarLixi Fixed-Ratio Combination in Type 2 Diabetes

Rosenstock J, Aronson R, Grunberger G, et al.

Diabetes Care
2016
View Source
Dosage Calculator
Calculate reconstitution volumes and injection amounts for Lixisenatide.
Open Calculator
Explore More
Explore more peptides in the Weight Loss category and related research.
View Weight Loss Category